Browsing by Author "Soy, Ebru"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Diaphragmatic Hernia After Pediatric Liver Transplant
    (2015) Kirnap, Mahir; Akdur, Aydincan; Ozcay, Figen; Soy, Ebru; Coskun, Mehmet; Moray, Gokhan; Haberal, Mehmet; 0000-0002-3462-7632; 0000-0002-8726-3369; 0000-0003-2498-7287; 0000-0002-5214-516X; 0000-0001-5630-022X; 0000-0002-0993-9917; 26450470; AAJ-8097-2021; AAA-3068-2021; AAE-1041-2021; ABG-5684-2020; AAM-4120-2021; AAC-5566-2019; AAH-9198-2019
    Diaphragmatic hernia is an unusual complication after pediatric liver transplant. Nearly half of bowel obstruction cases, which require surgical intervention in liver transplant patients, are caused by diaphragmatic hernia. The smaller patients are at risk for higher rates of diaphragmatic complication after pediatric liver transplant, but diaphragmatic hernia has not been reported as a unique occurrence. Here, we report 3 cases of diaphragmatic hernia after liver transplant and discuss the possible contributing factors. Diaphragmatic hernia should nevertheless be added to the list of potential complications after liver transplant in the pediatric population. Pediatric transplant physicians and surgeons should be aware of this complication so that it is recognized promptly in both acute and nonacute settings and appropriate action is taken.
  • No Thumbnail Available
    Item
    Early Bloodstream Infections Among Solid Organ Transplant Recipients
    (2016) Yesilkaya, Aysegul; Soy, Ebru; Ok, Mehtap Akcil; Azap, Ozlem Kurt; Arslan, Hande; Moray, Gokhan; Sezgin, Atilla; Berdan, Fatos; Haberal, Mehmet; https://orcid.org/0000-0002-0993-9917; https://orcid.org/0000-0002-3171-8926; https://orcid.org/0000-0002-5708-7915; https://orcid.org/0000-0003-2498-7287; https://orcid.org/0000-0002-3462-7632; AAC-5566-2019; AAZ-8170-2020; AAK-4089-2021; ABG-7034-2021; AAE-1041-2021; AAJ-8097-2021
  • No Thumbnail Available
    Item
    Liver Transplant for Fulminant Hepatic Failure: A Single-Center Experience
    (2015) Kirnap, Mahir; Akdur, Aydincan; Ozcay, Figen; Soy, Ebru; Yildirim, Sedat; Moray, Gokhan; Haberal, Mehmet; 0000-0002-8726-3369; 0000-0003-2498-7287; 0000-0002-3462-7632; 0000-0002-0993-9917; 0000-0002-5214-516X; 0000-0002-5735-4315; 26029995; AAH-9198-2019; AAA-3068-2021; AAE-1041-2021; AAJ-8097-2021; AAC-5566-2019; ABG-5684-2020; AAF-4610-2019
    Objectives: Acute liver failure is a life-threatening condition with sudden onset liver injury, decreased liver functions, hepatic encephalopathy, and coagulopathy in patients without preexisting liver disease. In this study, we sought to evaluate the results of liver transplant as a treatment for acute liver failure. Materials and Methods: Between November 1988 and March 2015, we performed 482 liver transplants in 471 patients. We performed 36 liver transplants in 35 patients because of acute liver failure. Only 5 of these were from deceased donors. Thirty of those 34 patients were pediatric (85%) and 5 were adults (15%). Results: Five patients died (4 in early postoperative period and 1 during the 18th month of living-donor liver transplant). We diagnosed 11 acute rejections (32%); 6 biliary leaks (17%); 6 intraabdominal hemorrhage (17%); 5 hepatic arterial thromboses (15%), and 1 venous complication (3%) during the early postoperative period. We have no morbidity or mortality in living-donor liver transplants. Conclusions: Living-donor liver transplants are an efficient and successful treatment for acute liver failure patients. In our center, we mostly consider and prefer living-donor liver transplants to deceased-donor liver transplant because of the paucity of organ donation, especially for pediatric patients. Considering acceptable postoperative complications, living-donor liver transplant is a lifesaving treatment for acute liver failure.
  • No Thumbnail Available
    Item
    Outcomes of Patients With Hepatocellular Carcinoma After Liver Transplant
    (2015) Moray, Gokhan; Kirnap, Mahir; Akdur, Aydincan; Soy, Ebru; Tezcaner, Tugan; Boyvat, Fatih; Ozdemir, Handan; Haberal, Mehmet; 0000-0002-0993-9917; 0000-0002-8726-3369; 0000-0002-3462-7632; 0000-0002-3641-8674; 0000-0003-2498-7287; 0000-0002-7528-3557; 26640906; AAC-5566-2019; AAA-3068-2021; AAJ-8097-2021; AAD-9865-2021; F-4230-2011; AAH-9198-2019; AAE-1041-2021; X-8540-2019
    Objectives: Liver transplant is one of the few effective treatments for hepatocellular carcinoma. Our aim in this study was to evaluate the risk factors for hepatocellular carcinoma recurrence after liver transplant. Materials and Methods: In this retrospective study, conducted between October 1988 and March 2015, four hundred seventy-three liver transplants were performed at our institution. Of these, 231 were pediatric and 242 were adult. Among these patients, liver transplant was performed in 58 patients (12.3%) for treatment of hepatocellular carcinoma. Results: Hepatocellular carcinoma recurrence was detected in 14 patients (24.1%). Overall 5-year and 10-year survival rates of patients underwent liver transplant beyond the Milan criteria for hepatocellular carcinoma were 50.3% and 43.1%. Overall, 5- and 10-year survival rates of patients underwent liver transplant within the Milan criteria for hepatocellular carcinoma were 78.4% and 72.6%. The main predictive variable was whether the tumor had expensed beyond the Milan criteria. Conclusions: As expected, outcomes were significantly better in the Milan criteria group. Although the overall- and disease-free survival rates were promising in such a group of patients who had no better chance, it could be asserted that liver transplant is a safe and effective treatment option with promising results, even if the tumor expanse is beyond the Milan criteria.